Identity

Alias
Juvenile myelomonocytic leukemia (JMML) Juvenile myelomonocytic leukemia syndrome (JMML syndrome) Note The proper terminology of this disorder is controversial; many authors, including the European Working Group on MDS in Childhood favor the term JMML; another working group suggests using the term JMML syndrome with a qualifier with or without monosomy 7 or 7q-.
Clinics and pathology
Disease
JCML is a chronic myeloproliferative disorder that typically affects young children: more than 95% of cases are diagnosed before age 4.
Phenotype/cell stem origin
Evidence exists for leukemic involvement of CD34-positive stem cells and monocyte-macrophage, erythroid, and B-lymphoid lineages in cases with cytogenetic abnormalities.
Epidemiology
Annual incidence is estimated to be roughly 4/million; median age 1-4 yrs; sex ratio: 1.4M/1F.
Clinics
Splenomegaly, lymphadenopathy, and skin rash are common; typical peripheral blood findings include leukocytosis (usually less than 100 x 10 9 /L), monocytosis, and thrombocytosis with variable degree of left shift; myeloblasts average about 5% of total nucleated cells; elevation of fetal hemoglobin (hbF) very common; absence of the Philadelphia chromosome in all cases. Proposed clinical criteria from the International Juvenile Myelomonocytic Leukemia Working Group includes: 1. White blood cell count > 13 x 10 9 /L (corrected for nucleated red blood cells). 2. Absolute monocyte count >1 x 10 9 /L (corrected). 3. Presence of immature myeloid precursors (myelocytes, promyelocytes, and myeloblasts) in the peripheral blood. 4. Bone marrow aspirate revealing < 30% blasts 5. No Ph chromosome on cytogenetic assessment. About 15% of cases are associated with neurofibromatosis type 1 (NF-1 mutation).
Pathology
Blood: leukocytosis, monocytosis, left shift in myeloid maturation, circulating mucleated red blood cells. Bone marrow: hypercellular marrow with mildly increased M:E ratio (typically 5:1), dispersed erythroid elements, and decreased numbers of megakaryocytes; dyplasia is usually not prominent.
Treatment
Intensive chemotherapy and all trans retinoic have not been shown to induce durable remissions; complete remissions have been achieved with stem cell transplantation.
Prognosis
The disease is uniformly fatal when treated with conventional chemotherapy; among those who undergo bone marrow transplantations, the majority ultimately relapse, with an overall survival rate of 25%. 
36
Cytogenetics
Cytogenetics morphological
Other than the frequent association with monosomy 7, no consistent cytogenetic abnormalities have been identified; whether the infantile monosomy 7 syndrome is distinct from JCML is controversial.
Genes involved and proteins
Note Mechanisms of Oncogenesis: JCML patients show spontaneous growth of granulocyte-macrophage colony forming units (CFU-GM) from peripheral blood, which appears to be the result of hypersensitivity to GM-CSF, IL-3, or SCF; cases associated with NF-1 are likely to be the result of constitutive activation of the Ras pathway as a result of decreased GT Pase activity although there is also evidence of a GAP independent function; up to 30% of cases show mutations in K-ras and N-ras; the importance of the RAS pathway has been confirmed in mouse models with targeted disrupted of Nf-1; recently data suggest that TNFa produced by neoplastic cells may prevent expansion of hematopoietic progenitors.
